Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Melanoma 3Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Somatostatinoma 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Mesothelioma, Malignant 2Insulinoma 2Glucagonoma 2Gliosarcoma 2Gastrinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Islet Cell 2Brain Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solitary Fibrous Tumor, Pleural 1Primary Myelofibrosis 1Pheochromocytoma 1

Interventions

vandetanib 12cabozantinib 8selpercatinib 5Sorafenib 5Everolimus 5Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2pralsetinib 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1pentetreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Medullary × vatalanib × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡